(Q45399777)

14 December 2017

Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). (English)

1 reference

14 December 2017

1 reference

4

1 reference

14 December 2017

3

V Michael Holers

1 reference

14 December 2017

Kendra A Young

1

1 reference

PubMed ID

17925391

14 December 2017

Xiaojiang S Chen

series ordinal

2

1 reference

PubMed ID

17925391

14 December 2017

language of work or name

English

0 references

publication date

9 October 2007

1 reference

Journal of Biological Chemistry

14 December 2017

1 reference

14 December 2017

282

1 reference

14 December 2017

50

1 reference

14 December 2017

36614-36625

1 reference

Epstein-Barr virus and rheumatoid arthritis: is there a link?

14 December 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epstein-Barr virus and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Proteins of purified Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Structure of the Epstein-Barr virus major envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epstein-Barr virus promotes human monocyte survival and maturation through a paracrine induction of IFN-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Complement and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

CD21 is a ligand for CD23 and regulates IgE production

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Structure of complement receptor 2 in complex with its C3d ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

The electrostatic nature of C3d-complement receptor 2 association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M706324200

The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation

21 January 2018

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1128/JVI.70.8.5557-5563.1996

Identifiers

DOI

10.1074/JBC.M706324200

1 reference

14 December 2017

1 reference

PubMed ID

17925391